Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in adults with prurigo nodularis
CTR20242960Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1819 in prurigo nodularis (PN), sponsored by Hengrui Therapeutics. Started Sep 2024; status: active.
02
Drugs
SHR-1819
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20242960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242960.